Enhanced Catalytic Performance of P450 Monooxygenase CYP11B1 by Constructing Fusion Protein with Preferred Reductase Domain and Linker.

Junfeng Liu, Aoxue Dong, Luo Liu

Abstract read

In one paragraph

Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Junfeng LiuBeijing Bioprocess Key Laboratory, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China. liujf@mail.buct.edu.cn.ORCID http://orcid.org/0000-0002-6737-9794

Aoxue DongBeijing Bioprocess Key Laboratory, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.

Luo LiuBeijing Bioprocess Key Laboratory, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China. liuluo@buct.edu.cn.

Funding

National Key Research and Development Program 2021YFC2101000

6 · The paper itself

Abstract

As promising biocatalysts, cytochrome P450 enzymes (CYP450s) participate in various reactions involving complex organic compounds. However, their broader application potential is constrained by the dependence on reductase domains. In this study, we engineered a self-sufficient P450 chimeric enzyme by fusing 11β-hydroxylase CYP11B1 with distinct reductase domains from P450

Indexed as

Recombinant Fusion ProteinsSteroid 11-beta-HydroxylaseBiocatalysisProtein DomainsProtein EngineeringRecombinant Fusion ProteinsSteroid 11-beta-HydroxylaseCatalytic performenceCytochrome P450Fusion proteinLinkerReductase

Identifiers

PMID41196557

DOI10.3390/ijms23073618

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.